Table 4.
Negative and positive percentage agreement between IHC assays at clinically relevant PDL1 expression cutoff levels.
| Probability of negative Test B, given negative Test A | ||||||
|---|---|---|---|---|---|---|
| Test A | Test B | |||||
| SP142 | SP263 | 22C3 | ||||
| First-line | Second-line | First-line | Second-line | First-line | Second-line | |
| SP142 | — | — | 92% | 85% | 97% | 65% |
| SP263 | 91% | 98% | — | — | 99% | 76% |
| 22C3 | 88% | 99% | 91% | 99% | — | — |
| Probability of positive Test B, given positive Test A | ||||||
| SP142 | — | — | 65% | 76% | 48% | 94% |
| SP263 | 68% | 28% | — | — | 57% | 98% |
| 22C3 | 82% | 17% | 93% | 49% | — | — |
PCR - polymerase chain reaction, IHC – immunohistochemistry.